Menu

Dr. Scott Franczek, MD

Publications

  • Franczek, S.P., Williams R.P., and Hull, S.I. 1986. A survey of potential virulence factors in clinical and environmental isolates of Serratia marcescens. J. Med. Microbiology. 22:151-156

Research & Protocols

  • Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of XXX in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (AD), 2016.
  • Principal Investigator: A Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of XXX in Subjects who are Asymptomatic at Risk for Developing Alzheimer’s Dementia, 2017.
  • Principal Investigator: A Placebo-Controlled, Double Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of XXX in Subjects with Early Alzheimer’s Disease, 2017.
  • Principal Investigator: Effect of XXX on Alzheimer’s Disease Progression as Measured by Cerebral 18F-AV1451 Tau-PET in Mild Alzheimer’s Disease Dementia, 2016.
  • Sub-Investigator: Multiple-Dose, Dose-Escalation Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of XXX in Patients with Mild Cognitive Impairment due to Alzheimer’s Disease or Mild to Moderate Alzheimer’s Dementia, 2016.
  • Sub-Investigator: A 24-Month Multi-Center, Randomized, Double Blind, Placebo-Controlled, Parallel-Group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of XXX in Early Alzheimer’s Disease, 2016.
  • Principal Investigator: A Double Blind, Multi-Center, Randomized, Sham-Controlled, Parallel Group Comparison of the dermaPACE Device in Conjunction with Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers, 2016.
  • Principal Investigator: A Randomized, Double-Blind, Parallel-Group, Vehicle and Standard of Care-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of XXX in Treating Non-healing Foot Ulcers in Subjects with Diabetes Mellitus, 2016.
  • Principal Investigator: A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Subjects with Type 2 Diabetes who have Inadequate Glycemic Control with Diet and Exercise, 2016.
  • Principal Investigator: A Phase-3B, Multicenter, Open Label Study to Evaluate the long-time Safety and Efficacy of Subcutaneous XXX in Patients with Systematic Lupus Erythematosus (SLE), 2016.
  • Principal Investigator: Pharmacokinetic Evaluations of XXX Following Subcutaneous Administration by Prefilled Syringe or Auto-Injector in Patients with Systemic Lupus Erythematosus, 2016.
  • Principal Investigator: A Multicenter, Open-Label Safety and Tolerability Extension Trial of XXX Daily in the Treatment of Chronic Idiopathic Constipation, 2016.
  • Principal Investigator: A Multicenter, Randomized, Partial-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived XXX Inhibitor in Subjects with New on-Set Type 1 Diabetes Mellitus, 2016.
  • Principal Investigator: A Multi-Center, Double-Blind, Randomized Vehicle-Controlled, Parallel- Group Study to Compare Perrigo XXX Cream, X% with ZOVIRAX® (Acyclovir) Cream 5%, and both Active Treatments to a Vehicle Control in Treatment of Recurrent Herpes Simplex Labialis, 2016.
  • Principal Investigator: A Phase III, Randomized, Open-Label, Comparative Study of Intravenous Iron XXX (Monofer®) and Iron Sucrose in Subjects with Iron Deficiency Anemia and who are Intolerant or Unresponsive to Oral Iron Therapy or who need Iron rapidly (PROVIDE), 2016.
  • Principal Investigator: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of XXX Administered to Patients with Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis, 2016.
  • Principal Investigator: Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, AND Tolerability of XXX, in Reducing the Occurrence Of Major Cardiovascular Events In High Risk Subjects, 2016.
  • Principal Investigator: A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical XXX-Collagen Sponge in Combination with Systemic Antibiotic Therapy in Diabetic Patients with an Infected Foot Ulcer, 2016.
  • Principal Investigator: Performance Evaluation: HIV combi PT on the XXX Immunoassay Analyzer (HIV+), 2016.
  • Principal Investigator: Performance Evaluation: HIV combi PT on the XXX Immunoassay Analyzer (Peds), 2016.
  • Principal Investigator: Performance Evaluation: HIV combi PT on the XXX Immunoassay Analyzer (Pregnant HR), 2016.
  • Principal Investigator: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of 2 Dose Levels of VX-787 Administered as Monotherapy and One Dose Level of XXX Administered in Combination with Oseltamivir for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects, 2016.
  • Principal Investigator: United States Piggy-Backed Health Economic Study of the Cost and Resource Utilization of a Topical Gentamicin-Collagen Sponge in Diabetic Patients with an Infected Foot Ulcer, 2016.
  • Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of XXX Administered Subcutaneously to Patients with Hypertriglyceridemia, 2016.
  • Principal Investigator: A Phase 3, Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety, Pharmacokinetics And Effectiveness Of Intravenous XXX in Elderly Subjects with Acute Uncomplicated Influenza Infection and in Subjects with Acute Uncomplicated Influenza Infection at Higher Risk for Influenza Complications, 2016.
  • Co-Investigator: “NCP Study Protocol XE5, Open Label Treatment of Refractory Partial Onset Seizures Using Vagus Nerve Stimulation, “Cyberonics, Inc., IRB # 284-96, Basim M Uthman, M.D. Principal Investigator, 1996.
  • Co-Investigator: “Long-Term Efficacy and Safety of Vagus Nerve Stimulation in the Treatment of Intractable Partial Seizures,” Cyberonics, Inc., #284-96, Basim M. Uthman, M.D., Principal Investigator, 1996.
  • Co-Investigator: “An Open Label Extension Study of Tiagabine HCI in the Treatment of Patients with Partial Seizures,” Abbot Laboratories Protocol M91-604, Basim M Uthman, M.D., 1995.
  • Co-Investigator: “N-Acetylcysteine (NAC) for the Prevention of Neuropsychological Morbidity Following Coronary Artery Bypass Graft Surgery,” Wendell Helveston, M.D., Principal Investigator, 1995.
  • Co-Investigator: “Double-Blind, Randomized, Parallel-Group, Single-Dose, Multi-Center, Safety, Tolerance, and Pharmacokinetic study of Intravenous Fosphenytoin (Cerebyx) versus intravenous Dilantin in Patients Requiring a Loading Dose of Phenytoin, “Protocol 982-26, Basim M. Uthman, M.D., Principal Investigator, 1995.
  • Co-Investigator: “N-Acetylcysteine in the Treatment of Neurodegenerative Disease, Protocol 470-93, Basim M. Uthman, M.D., Principal Investigator, 1995.
  • Co-Investigator: “NCP Study Protocol EO5: Assessment of Vagus Nerve stimulation (VNS) for Adjunctive Treatment of Epilepsy Patients Who Have Refractory Partial Onset Seizures with Alteration of Consciousness, “Cyberonics, Inc., IB#590-94, Basim M. Uthman, M.D., Principal Investigator, 1994.
  • Co-Investigator: “Conversion to Lamotrigine Monotherapy in Patients with Epilepsy, “Glaxo Wellcome, IRB#513094, Basim M. Uthman, M.D., Principal Investigator, 1994
  • Co-Investigator: “Treatment of Generalized Convulsion Status Epilepticus, “VA Coop Study #265, Basim M. Uthman, M.D., Principal Investigator, 1994
  • Co-Investigator: “Clinical Experience and the Use of Sabril in Patients with Partial Epilepsy,” Hoechst Marion Roussel Protocol VGPR-09, IRB#384-94, Basim M. Uthman, M.D., Principal Investigator, 1994.

Medical and Research Experience

Prior to beginning my medical career, my thesis work focused on the genetic analysis and molecular cloning a serine metalloproteinase from S. marcescens with subsequent biochemical characterization and protein analysis. I have teaching experience in Infectious Disease and have published my early work on the virulence factors in nosocomial isolates from Serratia marcescens.

  • 12+

    Years of Experience in Clinical Practice of General Neurology

  • 14+

    Years of Experience as an Educator and Mentor to All Levels of Health Care Professionals

  • 5+

    Years of Experience in the Clinical Trial Process

  • 35

    Principal/Sub/Co-Investigator of both Neurology and General Medicine Protocols